Test Center

My Recent Searches

  • No Recent Search.

My Tests Viewed

  • No Test Viewed.
Test Name

JAK2 V617F Mutation, Quantitative, Plasma-Based, Leumeta®

CPT Code(s)

81270

Methodology

Polymerase Chain Reaction (PCR) • Sequencing

Reference Range(s)

Interpretation: Negative

Clinical Significance

The JAK2 tyrosine kinase (V617F) was detected in most patients (>80%) with polycythemia vera (PV), 30-50% of patients with either essential thrombocythemia (ET) or myelofibrosis. The Quantitative measurement of V617F may be useful for assessing the correlation of tumor load/phenotype; monitoring/predicting the progression or responses of the disease when MPD patients are under therapy.

To view specimen requirements and codes please Select a regional laboratory.

Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)

Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.

16175
16175
16175
16175
16175
16175X
16175
16175
16175X
16175X
16175
16175
16175
16175
16175
16175
16175
16175X
16175
16175
JAK2 V617F Mutation, Quantitative, Plasma-Based, Leumeta®
16175